Primaquine
Primaquine (primaquine) is a small molecule pharmaceutical. Primaquine was first approved as Aralen phosphate w/ primaquine phosphate on 1982-01-01. It is used to treat falciparum malaria, malaria, and vivax malaria in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
Trade Name
FDA
EMA
Primaquine (discontinued: Primaquine)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| primaquine phosphate | ANDA | 2026-05-12 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
141 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Malaria | D008288 | EFO_0001068 | B54 | 9 | 16 | 21 | 23 | 22 | 84 |
| Vivax malaria | D016780 | EFO_0007445 | B51 | 3 | 10 | 18 | 12 | 18 | 57 |
| Falciparum malaria | D016778 | EFO_0007444 | B50 | 1 | 11 | 8 | 10 | 12 | 39 |
| Glucosephosphate dehydrogenase deficiency | D005955 | EFO_0007287 | — | 3 | 2 | 1 | 2 | 5 | 12 |
| Recurrence | D012008 | — | — | — | 1 | 2 | 2 | 6 | 10 |
| Pneumocystis pneumonia | D011020 | EFO_0007448 | B59 | — | — | 1 | 2 | 2 | 5 |
| Parasitic diseases | D010272 | EFO_0001067 | B88 | — | — | 1 | 1 | 1 | 3 |
| Infections | D007239 | EFO_0000544 | — | — | 1 | 1 | 1 | — | 3 |
| Pneumonia | D011014 | EFO_0003106 | J18 | — | — | — | 2 | 1 | 3 |
| Postpartum period | D049590 | — | — | — | — | — | 1 | — | 1 |
Show 2 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Asymptomatic diseases | D058070 | — | — | — | 1 | 2 | — | 2 | 4 |
| Hiv infections | D015658 | EFO_0000764 | B20 | — | — | 1 | — | 2 | 3 |
| Parasitemia | D018512 | — | — | — | — | 1 | — | 1 | 2 |
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | — | — | 1 | — | 1 | 2 |
| Covid-19 | D000086382 | — | U07.1 | — | 1 | 1 | — | — | 1 |
| Therapeutics | D013812 | — | — | — | — | 1 | — | — | 1 |
| Hemolysis | D006461 | — | — | — | — | 1 | — | — | 1 |
| Cardiotoxicity | D066126 | EFO_1001482 | — | — | — | 1 | — | — | 1 |
| Protozoan infections | D011528 | — | B50-B64 | — | — | 1 | — | — | 1 |
| Breast feeding | D001942 | — | — | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 7 | 1 | — | — | — | 7 |
| Pharmacokinetics | D010599 | — | — | 3 | 1 | — | — | — | 3 |
| Combination drug therapy | D004359 | — | — | 2 | 1 | — | — | — | 2 |
| Elimination disorders | D019960 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Obesity | D009765 | EFO_0001073 | E66.9 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Aids-related opportunistic infections | D017088 | — | — | — | — | — | — | 1 | 1 |
| Favism | D005236 | — | D55.0 | — | — | — | — | 1 | 1 |
| Mass drug administration | D000074381 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Primaquine |
| INN | primaquine |
| Description | Primaquine is an N-substituted diamine that is pentane-1,4-diamine substituted by a 6-methoxyquinolin-8-yl group at the N(4) position. It is a drug used in the treatment of malaria and Pneumocystis pneumonia. It has a role as an antimalarial. It is an aminoquinoline, a N-substituted diamine and an aromatic ether. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | COc1cc(NC(C)CCCN)c2ncccc2c1 |
Identifiers
| PDB | — |
| CAS-ID | 90-34-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL506 |
| ChEBI ID | 8405 |
| PubChem CID | 4908 |
| DrugBank | DB01087 |
| UNII ID | MVR3634GX1 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Primaquine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 8,987 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
294 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use